Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions

Doravirine (MK-1439) is a novel non-nucleoside reverse transcriptase inhibitor indicated for the combination treatment of human immunodeficiency virus type-1 (HIV-1) infection. The recommended dose is 100 mg once daily. This review summarizes the pharmacokinetics of doravirine, the influence of intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalilieh, Sauzanne, Yee, Ka Lai, Sanchez, Rosa, Stoch, S. Aubrey, Wenning, Larissa, Iwamoto, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511279/
https://www.ncbi.nlm.nih.gov/pubmed/32816220
http://dx.doi.org/10.1007/s40261-020-00934-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511279/
https://www.ncbi.nlm.nih.gov/pubmed/32816220
http://dx.doi.org/10.1007/s40261-020-00934-2

Ejemplares similares